Study Data from Mercy Catholic Medical Center Update Knowledge of Neuroendocrine Cancer (Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors).
In: Health & Medicine Week, 2024-06-07, S. 6594-6594
serialPeriodical
Zugriff:
A recent study conducted at Mercy Catholic Medical Center in Darby, Pennsylvania, explored the use of [177Lu]Lu-DOTATATE as a treatment for metastatic neuroendocrine tumors. Neuroendocrine tumors are often diagnosed at a metastatic stage, and current first-line treatments include somatostatin analogs, targeted therapies, and peptide receptor radionuclide therapy. The study found that [177Lu]Lu-DOTATATE showed promising results as a second, third, and fourth-line treatment for patients with non-ileal primaries and heavily pretreated disease. Further research is needed to investigate the efficacy of additional cycles of treatment. [Extracted from the article]
Copyright of Health & Medicine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Study Data from Mercy Catholic Medical Center Update Knowledge of Neuroendocrine Cancer (Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors).
|
---|---|
Zeitschrift: | Health & Medicine Week, 2024-06-07, S. 6594-6594 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6459 (print) |
Sonstiges: |
|